Who makes BIBP-Rec-Vaccine?

BIBP-Rec-Vaccine is developed by National Vaccine and Serum Institute, China.

What development phase is BIBP-Rec-Vaccine in?

BIBP-Rec-Vaccine is in Phase 3.

What are the side effects of BIBP-Rec-Vaccine?

Common side effects include Injection site reactions, Fever, Fatigue.

Last reviewed 2026-04-22 · How we verify

BIBP-Rec-Vaccine

National Vaccine and Serum Institute, China · Phase 3 active Biologic

BIBP-Rec-Vaccine is a recombinant protein-based vaccine designed to stimulate immune responses against specific disease targets.

At a glance

Generic name	BIBP-Rec-Vaccine
Sponsor	National Vaccine and Serum Institute, China
Drug class	vaccine
Modality	Biologic
Therapeutic area	Immunology
Phase	Phase 3

Mechanism of action

As a recombinant vaccine, BIBP-Rec-Vaccine uses engineered protein antigens to trigger both humoral and cellular immune responses. The vaccine is intended to provide protective immunity by priming the adaptive immune system to recognize and respond to the target pathogen or disease antigen.

Approved indications

No approved indications tracked.

Common side effects

Injection site reactions
Fever
Fatigue

Key clinical trials

Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BIBP-Rec-Vaccine CI brief — competitive landscape report
BIBP-Rec-Vaccine updates RSS · CI watch RSS
National Vaccine and Serum Institute, China portfolio CI